NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01996306,A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC,https://clinicaltrials.gov/study/NCT01996306,AXEPT,COMPLETED,The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.,NO,Colorectal Neoplasms|Neoplasm Metastasis|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms,BIOLOGICAL: Bevacizumab|DRUG: CPT-11 (Irinotecan)|DRUG: 5-FU Bolus|DRUG: 5-FU Infusion|DRUG: l-LV (dl-LV)|BIOLOGICAL: bevacizumab|DRUG: CPT-11 (Irinotecan)|DRUG: Capecitabine,"Overall survival, Time from the date of enrollment to death from any cause., Assessed until 1.5 years after the last patient enrolment","Progression-free survival (PFS), Time from the date of enrollment to the earlier of the date of confirmed progression or death from any cause., Assessed until 1.5 years after the last patient enrolment|Time to treatment failure (TTF), Time from the date of enrollment to the earlier of the date of confirmed progression, death from any cause, or discontinuation of protocol treatment., Assessed until 1.5 years after the last patient enrolment|Overall Response Rate (ORR), Proportion of eligible patients with measurable lesions with a best overall response of CR or PR assessed by the attending physician., Assessed at 6, 12 week and thereafter every 8 weeks|Disease Control Rate (DCR), Proportion of best overall response of CR, PR, or SD assessed by the attending physician., Assessed at 6, 12 week and thereafter every 8 weeks|Relative Dose Intensity, will be calculated for each drug to evaluate treatment compliance in the all-treated population during the observation period., Assessed until final dosing to the last patient|Incidence of Adverse Events (Adverse Reactions), The incidence of worst-grade adverse events (toxicities) on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm in all treated patients for the following events., Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery|Correlation between UGT1A1 genotype and safety, The incidence of worst-grade adverse events on study as graded by NCI-CTCAE v 4.0 will be determined by treatment arm and UGT1A1 genotype in all treated patients with a known UGT1A1 genotype profile, Adverse events occurring within 30 days after treatment discontinuation will be followed until recovery",,Epidemiological and Clinical Research Information Network,,ALL,"ADULT, OLDER_ADULT",PHASE3,650,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,AXEPT|UMIN000012263,2013-12-02,2017-11-20,2018-06-30,2013-11-27,,2019-01-08,"NPO Epidemiological and Clinical Research Information Network (ECRIN), Kyoto, 606-8392, Japan",
